Altered Plasma Fatty Acid Abundance Is Associated with Cachexia in Treatment-Naïve Pancreatic Cancer

Kristyn Gumpper-Fedus; Phil A. Hart; Martha A. Belury; Olivia Crowe; Rachel M. Cole; Valentina Pita Grisanti; Niharika Badi; Sophia Liva; Alice Hinton; Christopher Coss; Mitchell L. Ramsey; Anne Noonan; Darwin L. Conwell; Zobeida Cruz-Monserrate

doi:10.3390/cells11050910

Altered Plasma Fatty Acid Abundance Is Associated with Cachexia in Treatment-Naïve Pancreatic Cancer

Kristyn Gumpper-Fedus, Phil A. Hart, Martha A. Belury, Olivia Crowe, Rachel M. Cole, Valentina Pita Grisanti, Niharika Badi, Sophia Liva, Alice Hinton, Christopher Coss, Mitchell L. Ramsey, Anne Noonan, Darwin L. Conwell, Zobeida Cruz-Monserrate

Internal Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Cachexia occurs in up to 80% of pancreatic ductal adenocarcinoma (PDAC) patients and is characterized by unintentional weight loss and tissue wasting. To understand the metabolic changes that occur in PDAC-associated cachexia, we compared the abundance of plasma fatty acids (FAs), measured by gas chromatography, of subjects with treatment-naïve metastatic PDAC with or without cachexia, defined as a loss of >2% weight and evidence of sarcopenia (n = 43). The abundance of saturated, monounsaturated, and polyunsaturated FAs was not different between subjects with cachexia and those without. Oleic acid was significantly higher in subjects with cachexia (p = 0.0007) and diabetes (p = 0.015). Lauric (r = 0.592, p = 0.0096) and eicosapentaenoic (r = 0.564, p = 0.015) acids were positively correlated with age in cachexia patients. Subjects with diabetes (p = 0.021) or both diabetes and cachexia (p = 0.092) had low palmitic:oleic acid ratios. Linoleic acid was lower in subjects with diabetes (p = 0.018) and correlated with hemoglobin (r = 0.519, p = 0.033) and albumin (r = 0.577, p = 0.015) in subjects with cachexia. Oleic or linoleic acid may be useful treatment targets or biomarkers of cachexia in patients with metastatic PDAC, particularly those with diabetes.

Original language	English
Article number	910
Journal	Cells
Volume	11
Issue number	5
DOIs	https://doi.org/10.3390/cells11050910
State	Published - Mar 1 2022

Bibliographical note

Funding Information:
Funding: Research in this publication was supported by grants from the National Center for Advancing Translational Sciences (TL1TR002735 to K.G.-F.), the National Cancer Institute (R21CA256409 to Z.C.-M., P.A.H., M.A.B., and C.C. and R21209566 to M.A.B.), the USDA National Institute of Food and Agriculture Hatch Project (M.A.B.), and by the National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseases (U01DK108327 to D.L.C., Z.C.-M., P.A.H.). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.

Publisher Copyright:
© 2022 by the authorsLicensee MDPI, Basel, Switzerland.

Keywords

Albumin
Diabetes
Fatty acids
Hemoglobin
Linoleic acid
Oleic acid
Pancreatic cancer
Sarcopenia

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology (all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cells11050910

Cite this

Gumpper-Fedus, K., Hart, P. A., Belury, M. A., Crowe, O., Cole, R. M., Grisanti, V. P., Badi, N., Liva, S., Hinton, A., Coss, C., Ramsey, M. L., Noonan, A., Conwell, D. L., & Cruz-Monserrate, Z. (2022). Altered Plasma Fatty Acid Abundance Is Associated with Cachexia in Treatment-Naïve Pancreatic Cancer. Cells, 11(5), Article 910. https://doi.org/10.3390/cells11050910

@article{7d10c5a5bc6246868682dd1922606ce3,

title = "Altered Plasma Fatty Acid Abundance Is Associated with Cachexia in Treatment-Na{\"i}ve Pancreatic Cancer",

abstract = "Cachexia occurs in up to 80% of pancreatic ductal adenocarcinoma (PDAC) patients and is characterized by unintentional weight loss and tissue wasting. To understand the metabolic changes that occur in PDAC-associated cachexia, we compared the abundance of plasma fatty acids (FAs), measured by gas chromatography, of subjects with treatment-na{\"i}ve metastatic PDAC with or without cachexia, defined as a loss of >2% weight and evidence of sarcopenia (n = 43). The abundance of saturated, monounsaturated, and polyunsaturated FAs was not different between subjects with cachexia and those without. Oleic acid was significantly higher in subjects with cachexia (p = 0.0007) and diabetes (p = 0.015). Lauric (r = 0.592, p = 0.0096) and eicosapentaenoic (r = 0.564, p = 0.015) acids were positively correlated with age in cachexia patients. Subjects with diabetes (p = 0.021) or both diabetes and cachexia (p = 0.092) had low palmitic:oleic acid ratios. Linoleic acid was lower in subjects with diabetes (p = 0.018) and correlated with hemoglobin (r = 0.519, p = 0.033) and albumin (r = 0.577, p = 0.015) in subjects with cachexia. Oleic or linoleic acid may be useful treatment targets or biomarkers of cachexia in patients with metastatic PDAC, particularly those with diabetes.",

keywords = "Albumin, Diabetes, Fatty acids, Hemoglobin, Linoleic acid, Oleic acid, Pancreatic cancer, Sarcopenia",

author = "Kristyn Gumpper-Fedus and Hart, {Phil A.} and Belury, {Martha A.} and Olivia Crowe and Cole, {Rachel M.} and Grisanti, {Valentina Pita} and Niharika Badi and Sophia Liva and Alice Hinton and Christopher Coss and Ramsey, {Mitchell L.} and Anne Noonan and Conwell, {Darwin L.} and Zobeida Cruz-Monserrate",

note = "Funding Information: Funding: Research in this publication was supported by grants from the National Center for Advancing Translational Sciences (TL1TR002735 to K.G.-F.), the National Cancer Institute (R21CA256409 to Z.C.-M., P.A.H., M.A.B., and C.C. and R21209566 to M.A.B.), the USDA National Institute of Food and Agriculture Hatch Project (M.A.B.), and by the National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseases (U01DK108327 to D.L.C., Z.C.-M., P.A.H.). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. Publisher Copyright: {\textcopyright} 2022 by the authorsLicensee MDPI, Basel, Switzerland.",

year = "2022",

month = mar,

day = "1",

doi = "10.3390/cells11050910",

language = "English",

volume = "11",

number = "5",

}

TY - JOUR

T1 - Altered Plasma Fatty Acid Abundance Is Associated with Cachexia in Treatment-Naïve Pancreatic Cancer

AU - Gumpper-Fedus, Kristyn

AU - Hart, Phil A.

AU - Belury, Martha A.

AU - Crowe, Olivia

AU - Cole, Rachel M.

AU - Grisanti, Valentina Pita

AU - Badi, Niharika

AU - Liva, Sophia

AU - Hinton, Alice

AU - Coss, Christopher

AU - Ramsey, Mitchell L.

AU - Noonan, Anne

AU - Conwell, Darwin L.

AU - Cruz-Monserrate, Zobeida

N1 - Funding Information: Funding: Research in this publication was supported by grants from the National Center for Advancing Translational Sciences (TL1TR002735 to K.G.-F.), the National Cancer Institute (R21CA256409 to Z.C.-M., P.A.H., M.A.B., and C.C. and R21209566 to M.A.B.), the USDA National Institute of Food and Agriculture Hatch Project (M.A.B.), and by the National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseases (U01DK108327 to D.L.C., Z.C.-M., P.A.H.). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. Publisher Copyright: © 2022 by the authorsLicensee MDPI, Basel, Switzerland.

PY - 2022/3/1

Y1 - 2022/3/1

N2 - Cachexia occurs in up to 80% of pancreatic ductal adenocarcinoma (PDAC) patients and is characterized by unintentional weight loss and tissue wasting. To understand the metabolic changes that occur in PDAC-associated cachexia, we compared the abundance of plasma fatty acids (FAs), measured by gas chromatography, of subjects with treatment-naïve metastatic PDAC with or without cachexia, defined as a loss of >2% weight and evidence of sarcopenia (n = 43). The abundance of saturated, monounsaturated, and polyunsaturated FAs was not different between subjects with cachexia and those without. Oleic acid was significantly higher in subjects with cachexia (p = 0.0007) and diabetes (p = 0.015). Lauric (r = 0.592, p = 0.0096) and eicosapentaenoic (r = 0.564, p = 0.015) acids were positively correlated with age in cachexia patients. Subjects with diabetes (p = 0.021) or both diabetes and cachexia (p = 0.092) had low palmitic:oleic acid ratios. Linoleic acid was lower in subjects with diabetes (p = 0.018) and correlated with hemoglobin (r = 0.519, p = 0.033) and albumin (r = 0.577, p = 0.015) in subjects with cachexia. Oleic or linoleic acid may be useful treatment targets or biomarkers of cachexia in patients with metastatic PDAC, particularly those with diabetes.

AB - Cachexia occurs in up to 80% of pancreatic ductal adenocarcinoma (PDAC) patients and is characterized by unintentional weight loss and tissue wasting. To understand the metabolic changes that occur in PDAC-associated cachexia, we compared the abundance of plasma fatty acids (FAs), measured by gas chromatography, of subjects with treatment-naïve metastatic PDAC with or without cachexia, defined as a loss of >2% weight and evidence of sarcopenia (n = 43). The abundance of saturated, monounsaturated, and polyunsaturated FAs was not different between subjects with cachexia and those without. Oleic acid was significantly higher in subjects with cachexia (p = 0.0007) and diabetes (p = 0.015). Lauric (r = 0.592, p = 0.0096) and eicosapentaenoic (r = 0.564, p = 0.015) acids were positively correlated with age in cachexia patients. Subjects with diabetes (p = 0.021) or both diabetes and cachexia (p = 0.092) had low palmitic:oleic acid ratios. Linoleic acid was lower in subjects with diabetes (p = 0.018) and correlated with hemoglobin (r = 0.519, p = 0.033) and albumin (r = 0.577, p = 0.015) in subjects with cachexia. Oleic or linoleic acid may be useful treatment targets or biomarkers of cachexia in patients with metastatic PDAC, particularly those with diabetes.

KW - Albumin

KW - Diabetes

KW - Fatty acids

KW - Hemoglobin

KW - Linoleic acid

KW - Oleic acid

KW - Pancreatic cancer

KW - Sarcopenia

UR - http://www.scopus.com/inward/record.url?scp=85125995386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125995386&partnerID=8YFLogxK

U2 - 10.3390/cells11050910

DO - 10.3390/cells11050910

M3 - Article

C2 - 35269531

AN - SCOPUS:85125995386

VL - 11

JO - Cells

JF - Cells

IS - 5

M1 - 910

ER -

Altered Plasma Fatty Acid Abundance Is Associated with Cachexia in Treatment-Naïve Pancreatic Cancer

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this